MSCI Inc (NYSE: MSCI) reported fiscal 2024 fourth-quarter revenue growth of 7.7% year-on-year to $743.5 million, missing the analyst consensus estimate of $744.8 million.
The adjusted EPS of $4.18 beat the analyst consensus estimate of $3.95.
The total run rate on December 31, 2024, rose 8.8% Y/Y to $2.92 billion.
Also Read: Google Wants To Indulge In Workforce Training and Global Policy Discussions On AI
The organic recurring subscription run rate growth was 7.9%. The retention rate was 93.1% compared to 93.6% last year.
The investment research firm’s index operating revenues rose 8.3% year over year to $420.2 million, aided by higher recurring subscription revenues and asset-based fees.
Analytics operating revenues increased 4.9% Y/Y to $172.8 million, driven by higher recurring subscription revenues from equity and multi-asset class analytics products.
ESG and climate operating revenues grew 11.8% year over year to $85.2 million, driven by solid growth in ratings, screening and climate products.
All Other – private assets operating revenues improved 6.9% Y/Y to $65.3 million.
Margin: The operating margin improved from 53.7% to 54.5%. The adjusted EBITDA margin improved from 60.1% to 60.8%.
MSCI generated $394.68 million in free cash flow and held $409.4 million in cash and equivalents as of December 31, 2024.
Dividend: The board declared a dividend per share of $1.80 for the first quarter, marking a growth of 12.5%.
Chair and CEO Henry A. Fernandez said fourth-quarter highlights included its best-ever recurring sales in Index, 15% fixed income run-rate growth across its product lines, and 15% asset-based fees run-rate growth.
FY25 Outlook: MSCI projected operating expenses of $1.405 billion– $1.445 billion, capex of $115–$125 million, and free cash flow of $1.400 billion–$1.460 billion.
MSCI stock surged over 14% in the last 12 months.
Price Action: MSCI stock traded lower by 1.33% at $619.99 premarket at last check Wednesday.
Also Read:
Photo: Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.